Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study

[1] van der Esch M(2015)Clinical phenotypes in patients with knee osteoarthritis: a study in the Amsterdam osteoarthritis cohort Osteoarthr Cartil 23 544-549

[2] Knoop J(2011)Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the osteoarthritis initiative Arthritis Care Res (Hoboken) 63 1535-1542

[3] van der Leeden M(2015)Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis Rheumatology (Oxford) 54 588-600

[4] Roorda LD(2013)Osteoarthritis, inflammation and obesity Curr Opin Rheumatol 25 114-118

[5] Lems WF(2009)Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data Postgrad Med 121 9-20

[6] Knol DL(2018)Is abnormal glucose tolerance or diabetes a risk factor for knee, hip, or hand osteoarthritis? A systematic review Semin Arthritis Rheum 48 176-189

[7] Dekker J(2015)Metformin and inflammation: its potential beyond glucose-lowering effect Endocr Metab Immune Disord Drug Targets 15 196-205

[8] Knoop J(2014)Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (meloxicam) in patients with knee osteoarthritis Int J Sci Nature 5 277-282

[9] van der Leeden M(2014)Evaluation of the clinical use of metformin or pioglitazone in combination with meloxicam in patients with knee osteoarthritis; using knee injury and osteoarthritis outcome score Iraqi J Pharm Sci 23 13-23

[10] Thorstensson CA(2018)Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan PLoS One 13 1833-1840

[1] van der Esch M(2015)Clinical phenotypes in patients with knee osteoarthritis: a study in the Amsterdam osteoarthritis cohort Osteoarthr Cartil 23 544-549

[2] Knoop J(2011)Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the osteoarthritis initiative Arthritis Care Res (Hoboken) 63 1535-1542

[3] van der Leeden M(2015)Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis Rheumatology (Oxford) 54 588-600

[4] Roorda LD(2013)Osteoarthritis, inflammation and obesity Curr Opin Rheumatol 25 114-118

[5] Lems WF(2009)Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data Postgrad Med 121 9-20

[6] Knol DL(2018)Is abnormal glucose tolerance or diabetes a risk factor for knee, hip, or hand osteoarthritis? A systematic review Semin Arthritis Rheum 48 176-189

[7] Dekker J(2015)Metformin and inflammation: its potential beyond glucose-lowering effect Endocr Metab Immune Disord Drug Targets 15 196-205

[8] Knoop J(2014)Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (meloxicam) in patients with knee osteoarthritis Int J Sci Nature 5 277-282

[9] van der Leeden M(2014)Evaluation of the clinical use of metformin or pioglitazone in combination with meloxicam in patients with knee osteoarthritis; using knee injury and osteoarthritis outcome score Iraqi J Pharm Sci 23 13-23

[10] Thorstensson CA(2018)Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan PLoS One 13 1833-1840